|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer显示文摘MicroRNAs (miRNAs ) 玩在在各种各样的癌症的发展和前进的关键角色。不正常的 miR-9 表示仍然保持模糊,并且卵巢的癌症的变形前进上的一致都没被到达。在这研究,从生物信息学分析的结果证明 E-cadherin mRNA 的 3-UTR 被 miR-9 直接调整。酶记者试金结果证实 miR-9 能直接指向这 3-UTR。在卵巢的癌症织物的 miR-9 和 E-cadherin 表示被 qRT-PCR 确定。移植和侵略被在 SKOV3 和 A2780 愈合弯屈和 Transwell 系统试金检测。qRT-PCR 和西方的污点被执行检测上皮 ? 间充质的联系转变的 mRNA 和蛋白质。Immunofluorescence 技术被用来分析表示和 E-cadherin, N-cadherin,和 vimentin 的 subcellular 本地化。结果证明 miR-9 经常与配对的主要的相比是在变形浆液的卵巢的癌症织物的 upregulated。miR-9 的 Upregulation 能 downregulate E-cadherin 的表示但是 upregulate 间充质的标记(N-cadherin 和 vimentin ) 的表示。miR-9 的 Overexpression 能在卵巢的癌症支持房间移植和侵略,并且这些进程能有效地经由 miR-9 禁止者被禁止。因此,我们的学习证明 miR-9 可以经由指向 E-cadherin 和一条新奇潜在的治疗学的途径控制卵巢的癌症的转移支持卵巢的癌症转移。 | Bo Zhou Hongbin Xu Meng Xia Chaoyang Sun Na Li Ensong Guo Lili Guo Wanying Shan Hao Lu Yifan Wu Yuan Li Degui Yang Danhui Weng Li Meng Junbo Hu Ding Ma Gang Chen Kezhen Li | 2017 | Frontiers of Medicine2017，11，2： | 10 |
| 2 | Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial显示文摘We aimed to evaluate the effectiveness and safety of single-course initial regimens in patients with low-risk gestational trophoblastic neoplasia(GTN).In this trial (NCT01823315),276 patients were analyzed.Patients were allocated to three initiated regimens:single-course methotrexate(MTX),single-course MTX+dactinomycin(ACTD),and multi-course MTX(control arm).The primary endpoint was the complete remission(CR)rate by initial drug(s).The primary CR rate was 64.4%with multi-course MTX in the control arm.For the single-course MTX arm,the CR rate was 35.8%by one course;it increased to 59.3%after subsequent multi-course MTX,with non-inferiority to the control(difference-5.1%,95%confidence interval(CI)-19.4%to 9.2%,P=0.014).After further treatment with multi-course ACTD,the CR rate(93.3%)was similar to that of the control(95.2%,P=0.577).For the single-course MTX+ACTD arm,the CR rate was 46.7%by one course,which increased to 89.1%after subsequent multi-course,with non-inferiority(difference 24.7%,95%CI 12.8%-36.6%,P<0.001)to the control.It was similar to the CR rate by MTX and further ACTD in the control arm(89.1%vs.95.2%,P=0.135).Four patients experienced recurrence,with no death,during the 2-year follow-up.We demonstrated that chemotherapy initiation with single-course MTX may be an alternative regimen for patients with low-risk GTN. | Lili Chen Ling Xi Jie Jiang Rutie Yin Pengpeng Qu Xiuqin Li Xiaoyun Wan Yaxia Chen Dongxiao Hu Yuyan Mao Zimin Pan Xiaodong Cheng Xinyu Wang Qingli Li Danhui Weng Xi Zhang Hong Zhang Quanhong Ping Xiaomei Liu Xing Xie Beihua Kong Ding Ma Weiguo Lu | 2022 | Frontiers of Medicine2022，16，2： | 2 |
| 3 | Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms显示文摘 | HuiJuan Wu Yang Cao Danhui Weng Hui Xing Xiaohong Song Jianfeng Zhou Gang Xu Yunping Lu Shixuan Wang Ding Ma | 2008 | Cancer Letters2008，，2： | 1 |
| 4 | Correlation of TWIST2 up-regulation and epithelial–mesenchymal transition during tumorigenesis and progression of cervical carcinoma显示文摘 | Yan Li Wei Wang Wenwen Wang Runfeng Yang Tian Wang Tiefen Su Danhui Weng Tao Tao Wei Li Ding Ma Shixuan Wang | 2011 | Gynecologic Oncology2011，，1： | 1 |
| 5 | Reversal of multidrug resistance and inhibition of phosphorylation of AKT in human ovarian cancer cell line by wild-type PTEN gene显示文摘 | Huijuan Wu Danhui Weng Hui Xing Yunping Lu Ding Ma | 2008 | Journal of Huazhong University of Science and Technology2008，，6： | 1 |
| 6 | Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy显示文摘 | Hui Xing Shixuan Wang Keqin Hu Wenming Tao Jing Li Qinglai Gao Xiaokui Yang Danhui Weng Yunpin Lu Ding Ma | 2005 | Journal of Cancer Research and Clinical Oncology2005，，8： | 1 |
| 7 | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer:a randomized,non-inferiority,multicenter trial显示文摘We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415–1.757;P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment. | Danhui Weng Huihua Xiong Changkun Zhu Xiaoyun Wan Yaxia Chen Xinyu Wang Youzhong Zhang Jie Jiang Xi Zhang Qinglei Gao Gang Chen Hui Xing Changyu Wang Kezhen Li Yaheng Chen Yuyan Mao Dongxiao Hu Zimin Pan Qingqin Chen Baoxia Cui Kun Song Cunjian Yi Guangcai Peng Xiaobing Han Ruifang An Liangsheng Fan Wei Wang Tingchuan Xiong Yile Chen Zhenzi Tang Lin Li Xingsheng Yang Xiaodong Cheng Weiguo Lu Hui Wang Beihua Kong Xing Xie Ding Ma | 2023 | Frontiers of Medicine2023，17，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员